Abstract. The efficacy of traditional chemoradiotherapies for pancreatic cancer remains limited, and no effective targeted therapies or screening tests are currently available. Therefore more individualized drug screening is warranted for the clinical treatment of pancreatic cancer. A patient-derived xenograft (PDX) model of pancreatic cancer bone metastasis was established, and next-generation sequencing (NGS) was used to investigate the molecular characteristics of the cancer and screen for potential drugs. Immunohistochemical analysis was performed to validate that the PDX retained the molecular characteristics from the patient. Using NGS technology, 13 pancreatic-cancer-associated polymorphisms/mutations were identified out of 416 genes sequenced. Based on the sequencing results and associated literatures, AZD6244, a highly selective inhibitor against mitogen-activated protein kinase kinase 1 (MEK1), was chosen as a potential therapy. AZD6244, a highly selective MEK1 inhibitor, was evaluated as effective for the pancreatic cancer PDX model, and thus may provide potential efficacy in the clinical treatment of the patient with pancreatic cancer investigated in the present study. The feasibility of the novel NGS-PDX based drug-screening pattern was demonstrated, and has a potential to improve individua lized treatment for cancer.
Introduction
Pancreatic cancer is expected to be the second most lethal malignancy in the USA by 2020, and the 5-year survival rate for patients diagnosed with locally advanced or metastatic pancreatic cancer remains <3% (1, 2) . The efficacy of traditional chemoradiotherapies for pancreatic cancer remains limited (3) (4) (5) . However, no effective targeted therapies or screening tests for pancreatic cancer are recently available, and no clinically comfirmed biomarkers are available for identifying subsets of patients who might benefit from chemoradiotherapies or targeted theprapies (6) (7) (8) (9) . Different from frequent liver and peritoneum metastases, the bone metastasis rate of pancreatic cancers is quite low but reaches higher of about 7.3% with the improvement of the diagnosis and treatment level (10, 11) . For pancreatic cancer patients, especially those in advanced or metastatic disease stages, individualized drug screening is urgently needed for the clinical treatment.
The lack of an appropriate in vivo model for preclinical studies has limited the mechanistic study of tumor resistance to anti-VEGF therapy. Patient-derived xenografts (PDXs), so-called Avatar models (12) , have been increasingly widely used in various types of cancers for translational research in recent years, with the greatest advantage of its ability to better predict clinical tumor response (13) . Accumulating evidence indicates that PDX is an reliable cancer research tool for drug screening and personalized medicine applications (14) .
It is known that somatic genomic alterations alter the function of genes or pathways, thus resulting in tumorigenesis, metastasis, and resistance to therapies (15, 16) . Therefore, precise molecular profiles of tumors will help to predict drug (17) . Understanding the genomic landscape of CRC can contribute to drug screening (8, (18) (19) (20) . Large-scale sequencing projects has economically led to the rapid development and clinical popularization of next-generation sequencing (NGS) technologies (21) . NGS can be a powerful tool to understand the genomic landscape of patients and mechanism of drug response, which thus might provide a more broad vision for clinically potential drug screening (22) (23) (24) . Therefore, NGS technologies are being used by pharmaceutical companies throughout the drug discovery process (21) .
In our previous studies, we established a series of PDX models of different tumor types and accumulated substantial experiences of drug evaluation, screening and mechanism exploration (25, 26) . While in the present study, we established a PDX model by pancreatic cancer bone metastasis tumor tissues for evaluation of potential drugs for pancreatic cancer patient. In our study, in order to select the optimal therapy for the patient, the NGS technology was used for investigating of tumor molecular characteristics and searching for potential drugs, which were finally evaluated in the corresponding PDX model. The aim of our study is to demonstrate the feasibility of the novel NGS-PDX based drug screening pattern which has a great potential to improve the cancer individualized treatment.
Materials and methods
Reagents and drugs. AZD6244 (cat. no. S1008) and Capecitabine (cat. no. S1156) were purchased from Selleck Chemicals (Shanghai, China). The antibodies against ki-67, CK19, CK7, PCNA, Caspase-3, ERK, p-ERK, and β-actin were purchased from Abcam (Cambridge, UK).
Patient and tumor tissues. Pancreatic cancer bone metastasis (diagnosed as adenocarcinoma) tissues were obtained at surgery from a 67-year-old female patient. A single bone metastasis was imageologically found at the right pedicle of L2 vertebral arch, which means a high risk of fracture and paraplegia. In addition, the patient urged for operation treatment. The study was done in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice guidelines. The Institutional Ethical Committee approved the current study.
Establishment of PDX model. BALB/c nude mice (3-to-4-week-old, female) were purchased from Shanghai Slaccas Laboratory Animal and housed in SPF laboratory animal rooms at laboratory animal center of Zhejiang University. Mice were acclimated to new environments for at least 3 days before use. Surgical tumor tissues were cut into pieces of 3 to 4 mm and transplanted within 30 min s.c. to mice. Additional tissues were snap-frozen and stored at -80˚C until use. Animals were monitored periodically for their weight with an electronic balance and tumor growth with a Vernier caliper twice every week. The tumor volume was calculated as formula V=LD x (SD) 2 /2, where V represents the tumor volume, LD and SD are the longest and the shortest tumor diameter, respectively. Tumors were then harvested, minced and re-implanted as described above for passaging. 
Multiple gene mutation analysis by next generation sequencing.
The sequencing including 416 gene exons was conducted by Geneseeq Technology Inc. (Nanjing, China). ctDNA was extracted from patient's tumor. The purified ctDNA is quantified by a Picogreen fluorescence assay using the provided lambda DNA standards (Invitrogen Life Technologies, Carlsbad, CA, USA). Then, library construction with the KAPA Hyper DNA Library Prep Kit, containing mixes for end repair, dA addition and ligation, were performed in 96-well plates (Eppendorf). Dual-indexed sequencing libraries are PCR amplified for 4-7 cycles. The 5'-biotinylated probe solution is provided as capture probes, the baits target 416 cancer-related genes. 1 µg of each ctDNA-fragment sequencing library is mixed with 5 µg of human Cot-1 DNA, 5 µg of salmon sperm DNA, and 1 unit adaptor-specific blocker DNA in hybridization buffer, heated for 10 min at 95˚C, and held for 5 min at 65˚C in the thermocycler. Within 5 min, the capture probes are added to the mixture, and the solution hybridization is performed for 16-18 h at 65˚C. After hybridization is complete, the captured targets are selected by pulling down the biotinylated probe/target hybrids using streptavidin-coated magnetic beads, and off-target library is removed by washing with wash buffer. The PCR master mix is added to directly amplify (6-8 cycles) the captured library from the washed beads. After amplification, the samples are purified by AMPure XP beads, quantified by qPCR (Kapa Biosystems, Inc., Wilmington, MA, USA) and sized on bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). Libraries are normali zed to 2.5 nM and pooled. Deep Sequencing is performed on Illumina HiSeq 4000 using PE75 V1 kit. Cluster generation and sequencing is performed according to manufacturer's protocol. Base calling was performed using bcl2fastq v2. 16 .0.10 (Illumina, Inc., San Diego, CA, USA) to generate sequence reads in FASTQ format (Illumina 1.8+ encoding). , then mice were randomized (6 mice with tumors per group and housed in per rearing cage) and dosing was administrated (AZD6244, 50 mg/kg p.o. qd; Capecitabine, 1.0 mM/kg p.o. qd) for 4 weeks. Mice were weighed for signs of toxicity and tumor size was evaluated once per week. TGI (Relative tumor growth inhibition) was calculated using the following formula: (1-T/C)%, where T means the relative tumor volume of the treated mice, and C means the relative tumor volume of the control mice.
Immunohistochemistry. Specimen were fixed by 10 neutral formalin, then embedded in paraffin, sectioned (5 µm thick) and placed on slides for marker analysis. Sections were incubated with the primary antibodies overnight at 4˚C, after blocking nonspecific antibody bindings. The strepta vidin-biotin peroxidase complex method (Lab Vision, Nairobi, Kenya) was used for immunohistochemistry. The slides were photographed using an Olympus BX60 (Olympus, Hamburg, Germany).
Statistical analysis.
Results were presented as mean ± SD. Calculation and statistics were performed with Excel 2010 (Microsoft Corporation, Redmond, WA, USA) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA were used to analyze the significance of differences among groups. P<0.05 was considered statistically significant.
Results

Patient characteristics and PDX model establishment.
Pancreatic cancer bone metastasis (diagnosed as adenocarcinoma) tissues obtained at surgery from a 67-year-old female patient were subcutaneously implanted into BALB/c nude mice for the PDX model establishment. Tumors were re-implanted in new mice after reaching a volume of 1,000 mm 3 as model passaging. The PDX model was serially passaged in animals 3 times. In order to further evaluate the PDX xenograft, immunohistochemical test was performed to identify if the patient's characteristics were retained in the PDX. Immunohistochemical expressions of CK19, CK7, and ki67 as well as the H&E staining showed that the pathological characteristics of the third passage xenograft was in accordance with the original patient sample (Fig. 1) .
Next generation sequencing for drug efficacy prediction.
The sequencing of pancreatic cancer bone metastasis tissues of the patient tumor was conducted by Geneseeq Technology Inc. Totally, 13 pancreatic cancer-associated gene polymorphisms/mutations were found out of the 416 genes sequenced (Tables I and II) . Based on the sequencing results and associated literatures, there were no under-clinical-trial targeted therapies of pancreatic cancer directly suitable for the genes detected. Therefore AZD6244 (AZD for short, also named as Selumetinib), a highly selective inhibitor against MEK1, was chosen as a potential therapy whose antitumor efficacy would then be evaluated in our PDX model. ACTB  DNM2  KIF1B  RARA  ADH1B  DOCK1  KIT  RASGEF1A  AIP  DOT1L  KMT2B  RB1  AKT1  DPYD  KMT2C  RECQL4  AKT2  DUSP2  KRAS  RELN  AKT3  EBF1  LEF1  RET  ALDH2  ECT2L  LMO1  RHBDF2  ALK  EED  LSP1  RHOA  AMER1  EGFR  LYN  RICTOR  AP3B1  EGR1  LYST  RNF146  APC  EP300  LZTR1  RNF43  AR  EPCAM  MAP2K1  ROS1  ARAF  EPHA3  MAP2K2  ROS1  ARID1A  ERBB2  MAP2K4  RPTOR  ARID2  ERBB3  MAP3K1  RRM1  ARID5B  ERBB4  MCL1  RUNX1  ASXL1  ERCC1  MDM2  SBDS  ATM  ERCC2  MDM4  SDHA  ATR  ERCC3  MECOM  SDHAF2  ATRX  ERCC4  MED12  SDHB  AURKA  ERCC5  MEF2B  SDHC  AURKB  ESR1  MEN1  SDHD  AXIN1  ETV1  MET  SERP2  AXL  ETV4  MGMT  SETBP1  B2M  EWSR1  MITF  SETD2  BAP1  EXT1  MLH1  SF3B1  BARD1  EXT2  MLL  SGK1  BAT3  EZH2  MLLT10  SH2D1A  BCL2  FANCA  MLPH  SLX4  BCL2L1  FANCB  MPL  SMAD2  BCL2L2  FANCC  MRE11A  SMAD3  BCORL1  FANCD2  MSH2  SMAD4  BIM(BCL2L11) FANCE  MSH3  SMAD7  BLM  FANCF  MSH6  SMARCA4  BMPR1A  FANCG  MTHFR  SMARCB1  BRAF  FANCI  MTOR  SMC1A  BRCA1  FANCL  MUTYH  SMC3  BRCA2  FANCM  MYC  SMO  BRD4  FAT1  MYCL1  SOX2  BRIP1  FBXO11  MYCN  SPOP  BTG2  FCGR2B  MYD88  SRC  BTK  FGF19  MYNN  SRSF2  BTLA  FGFR1  NBN  STAG2  BUB1B  FGFR2  NCSTN  STAT3  c11orf30  FGFR3  NF1  STAT5A  CALR  FGFR4  NF2  STAT5B  CBL  FH  NFKBIA  STIL  CCND1  FIP1L1  NKX2-1  STK11  CCNE1  FLCN  NOTCH1  STMN1  CCT6B  FLT1  NOTCH2  STX11  CD22  FLT3  NPM1  STXBP2  CD274  FLT4  NQO1  SUFU   Table II. Continued.   ABCC2  DMNT3A  KDR  RAF1   CD58  GADD45B NRAS  SUZ12  CD70  GATA1  NRG1  SYN3  CDA  GATA2  NSD1  TCN2  CDC73  GATA3  NT5C2  TEK  CDH1  GATA4  NTRK1  TEKT4  CDK10  GATA6  PAG1  TERC  CDK12  GNA11  PAK3  TERT  CDK4  GNA13  PALB2  TET2  CDK6  GNAQ  PARK2  TGFBR2  CDK8  GNAS  PAX5  TLE1  CDKN1B  GPC3  PBRM1  TLE4  CDKN1C  GRIN2A  PC  TMEM127  CDKN2A  GRM3  PDCD1  TMPRSS2  CDKN2B  GSTM1  PDCD1LG2 TNFAIP3  CDKN2C  GSTP1  PDGFRA  TNFRSF14  CEBPA  GSTT1  PDGFRB  TNFRSF17  CEP57  HBA1  PDK1  TNFRSF19  CHD4  HBA2  PHF6  TOP1  CHEK1  HBB  PHOX2B  TOP2A  CHEK2  HDAC1  PICK3R1  TP53  CKS1B  HDAC2  PIK3C3  TP63  CREBBP  HDAC4  PIK3CA  TPMT  CRKL  HDAC7  PIK3CD  TRAF2  CROT  HGF  PIK3R1  TRAF3  CSF1R  HNF1A  PIK3R2  TRAF5  CSF3R  HNF1B  PLCE1  TSC1  CTCF  HRAS  PLK1  TSC2  CTLA4  ID3  PMS1  TSHR  CTNNB1  IDH1  PMS2  TTF1  CUX1  IDH2  POLD1  TUBB3  CXCR4  IGF1R  POLD3  TYMS  CYLD  IGF2  POLE  TYR  CYP2B6  * 6  IKBKE  POT1  U2AF1  CYP2B6  * 6  IKZF1  PPP2R1A  UGT1A1  CYP2C19  * 2  IKZF2  PRDM1  UNC13D  CYP2C9  * 3  IKZF3  PRF1  VEGFA  CYP2D6  IL13  PRKAR1A  VHL  CYP2D6  * 3  IL7R  PRKCI  WISP3  CYP2D6  * 4  INPP4B  PTCH1  WRN  CYP2D6  * 6  INPP5D  PTEN  WT1  CYP3A4  * 4  IRF1  PTPN11  XIAP  CYP3A5  * 3  IRF2  PTPN2  XPA  DAB2  IRF4  PTPN6  XPC  DAXX  IRF8  PTPRO  XPO1  DDB2  JAK1  QKI  XRCC1  DDR2  JAK2  RAC1  YAP1  DDX1  JAK3  RAD21  ZAP70  DHFR  JARID2  RAD50  ZBTB20  DICER1  JUN  RAD51  ZNF217  DIS3L2  KDM2B  RAD51C  ZNF703  DLG2  KDM5A  RAD51D  ZRSR2 orally administration of AZD6244 (50 mg/kg), Capecitabine (1.0 mM/kg) or saline were then given once a day for 28 days. The mice were killed and excised tumors were measured. Then, relative tumor growth inhibition (TGI) was calculated as per the following formula: (1-T/C) %, where T is relative tumor volume of treated group mice, and C is relative tumor volume of control group mice. We found that single AZD6244 exhibited better efficacy (TGI, 33.03%) than Capecitabine (TGI, 26.93%), although without statistical significance. While the combination of both shown a significant synergistic effect, with TGI of 54.82% (Fig. 2) . By western blotting, we evaluated the changes of ERK and p-ERK expressions in all groups, to find that p-ERK expressions were significantly suppressed in both single and combined AZD6244 groups (Fig. 3) . By immunohistochemical staining, we found that PCNA (proliferating cell nuclear antigen) expressions in the AZD6244-treated groups were significantly suppressed, while caspase-3 (one of apoptosis associated antigens) expressions were significantly upregulated (Figs. 4 and 5) . Therefore, AZD6244 was evaluated effective for the pancreatic cancer PDX model, thus might provide potential efficay in the clinical treatment of the very pancreatic cancer patient.
Disscussion
Novel technologies contribute to the progress of the drug screening of pancreatic cancer during recent years. PDX models are being used for pancreatic cancer research in a series of studies (2, 7, 34, 35) , while NGS technologies contribute to the translational research of pancreatic cancer (36) (37) (38) . Multiple clinical studies have showed NGS and PDX will ameliorate personalized medicine and will be necessary for discovering novel therapeutic targets and biomarkers (39) . With the progress of these technologies, both are getting economically availble for patients. In our study, we combined PDX and NGS as an promising pattern of individualized drug screening to improve the clinical treatment of pancreatic cancer patients. The PDX model of pancreatic cancer bone metastasis we established was comfirmed as highly molecularly stable with clinical patients in our study. Immunohistochemical expressions of CK19, CK7, and ki67 as well as the H&E staining showed that the pathological characteristics of the third passage xenograft was in accordance with the original patient tumor. Therefore, our PDX model could be considered as an 'Avatar' or a 'stand-in' of our pancreatic cancer patient, which would be a quite promising platform for drug screeing and evaluation.
In order to select the potential therapies customized for the pancreatic cancer patient, the bone metastasis tumor tissues were used for NGS detection (Geneseeq Technology Inc). However, based on the sequencing results and associa ted literatures, we found no under-clinical-trial targeted therapies of pancreatic cancer directly suitable for the genes detected. The sequencing report from Geneseeq Technology Inc also provided the alternative drug treatment suggestions, and MEK1 inhibitor was one of the most promising targeted therapies suggested. Then we concentrated on MEK1, a downstream gene of KRAS, which might be a potential target for treatment. Therefore we chose AZD6244, a MEK1 inhibitor, as a potential therapy which would then be evaluated in our PDX model.
In our study, we found that single AZD6244 exhibited better efficacy than Capecitabine, although without statistical significance. While the combination of both shown a significant synergistic effect, with TGI of 54.82%. AZD6244 significantly suppressed p-ERK expressions of the pancreatic cancer PDX model. AZD6244 significantly suppressed tumor cell proliferation and upregulated tumor cell apoptosis. Several studies have evaluated the effect of AZD6244 in pancreatic cancer in preclinical and clinical phase, and AZD6244 was shown to be effective in combination with EGFR/PIK3CA/STAT3 inhibitors in patients with pancreatic cancer (40-42). While we have shown that AZD6244 also has a synergistic effect in combination with Capecitabine. In addition, it was suggested that AZD6244 alone was mainly cytostatic, and apoptosis was mainly induced by combination therapies targeting multiple pathways (43) . While here in the present study, we shown that AZD6244 also suppressed tumor cell proliferation as a sinlge agent. Therefore, AZD6244 was evaluated as effective for the pancreatic cancer PDX model, thus might provide potential efficay in the clinical treatment of this pancreatic cancer patient.
In our study, AZD6244, a highly selective MEK1 inhibitor, was evaluated as effective for the pancreatic cancer PDX model, and thus might provide potential efficay in the clinical treatment of this pancreatic cancer patient. Although only one targeted agent was evaluated, we have successfully shown PDX-NGS based drug screening as a novel promising pattern of individualized drug screening to improve the clinical treatment of pancreatic cancer patients.
